ArticleMolecular medicine reports2018
Anti‑IL‑39 (IL‑23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus‑like mice.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Cytokine multimerization: when more is more and sometimes less.Nature reviews. Immunology · 2026Review
- Evaluation of Serum IL-39 Levels in Patients with Polycystic Ovary Syndrome.Journal of clinical medicine · 2026Article
- Interleukin-39 aggravates sepsis by inducing self-sustaining neutrophil activation in the lungs via the CXCL1-CXCR2 pathway.International journal of biological sciences · 2026Article
- IL-39 and IL-35 gingival crevicular fluid levels in diabetic patients with generalized periodontitis.Clinical oral investigations · 2024Article
- Evaluation of IL-23p19/Ebi3 (IL-39) gingival crevicular fluid levels in periodontal health, gingivitis, and periodontitis.Clinical oral investigations · 2022Article
- IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity.Experimental hematology & oncology · 2022Article
- Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes.International journal of molecular sciences · 2021Article
- T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis.Inflammation · 2021Article
- Article
- Gm614 Protects Germinal Center B Cells From Death by Suppressing Caspase-1 Transcription in Lupus-Prone Mice.Frontiers in immunology · 2020Article
- Article
- Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?Annals of the rheumatic diseases · 2019Article
- IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer.Frontiers in oncology · 2019Review
- IL-39 acts as a friend to pancreatic cancer.Medical oncology (Northwood, London, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interleukin (IL)‑12 family cytokines have been examined as therapeutic targets in the treatment of several autoimmune diseases. Our previous study showed that a novel IL‑12 family cytokine, IL‑39 (IL‑23p19/Ebi3) mediates inflammation in lupus‑like mice. In the present study, the effect of anti‑mouse IL‑39 polyclonal antibodies on autoimmune symptoms in lupus‑like mice was investigated. Rabbit anti‑mouse IL‑39 polyclonal antibodies were produced by immunization with recombinant mouse IL‑39, and purified using protein A chromatography. These antibodies were subsequently used to treat lupus‑like mice. Flow cytometry, captured images, ELISA and H&E staining were used to determine the effect of anti‑IL‑39 polyclonal antibodies on inflammatory cells, autoantibody titers, proteinuria, infiltrating inflammatory cells and the structure of the glomerular region. The anti‑IL‑39 polyclonal antibodies effectively reduced the numbers of inflammatory cells, splenomegaly, autoantibody titers, proteinuria, infiltrating inflammatory cells, and restored the structure of the glomerular region in MRL/lpr mice. Taken together, these results suggested that anti‑IL‑39 polyclonal antibodies ameliorated autoimmune symptoms in lupus‑like mice. Therefore, IL‑39 may be used as a possible target for the treatment of systemic lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.